Emergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to Hold

Emergent BioSolutions (NYSE:EBS) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

A number of other analysts have also issued reports on the company. Benchmark boosted their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Price Performance

Emergent BioSolutions stock opened at $9.42 on Wednesday. The company’s 50 day simple moving average is $8.72 and its 200-day simple moving average is $8.17. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The company has a market capitalization of $510.38 million, a price-to-earnings ratio of -2.29 and a beta of 1.57.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. SeaCrest Wealth Management LLC boosted its position in Emergent BioSolutions by 3.2% in the 3rd quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after buying an additional 3,705 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 4,409 shares in the last quarter. CWM LLC grew its stake in Emergent BioSolutions by 32,706.7% during the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in Emergent BioSolutions during the 2nd quarter worth $41,000. Finally, Verus Capital Partners LLC purchased a new stake in Emergent BioSolutions during the 2nd quarter worth about $68,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.